Search results for: 'test ad measurement industry'

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD gro...

03 Oct 2022  |  Global  |  Market Research

Global Prenatal Genetic Testing—Forecast to 2026

Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients

Infographics

×

New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...

As healthcare evolves toward personalized solutions, everyday consumers are proactively taking responsibility for their health in ways unimaginable a decade ago. A direct-to-consumer genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider....

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...